Skip to main content

He said, she said, then they said...



Conflicting studies can make life tough. A good systematic review could sort it out. It might be possible for the studies to be pooled into a meta-analysis. That can show you the spread of individual study results and what they add up to, at the same time.

But what about when systematic reviews disagree? When the "he said, she said" of conflicting studies goes meta, it can be even more confusing. New layers of disagreement get piled onto the layers from the original research. Yikes! This post is going to be tough-going...

A group of us defined this discordance among reviews as: the review authors disagree about whether or not there is an effect, or the direction of effect differs between reviews. A difference in direction of effect can mean one review gives a "thumbs up" and another a "thumbs down."

Some people are surprised that this happens. But it's inevitable. Sometimes you need to read several systematic reviews to get your head around a body of evidence. Different groups of people approach even the same question in different but equally legitimate ways. And there are lots of different judgment calls people can make along the way. Those decisions can change the results the systematic review will get.

When and how they searched for studies - and what type and subject - means that it's not at all unusual for groups of reviewers to be looking at different sets of studies for much the same question.

After all that, different groups of people can interpret evidence differently. They often make different judgments about the quality of a study or part of one - and that could dramatically affect its value and meaning to them.

It's a little like watching a game of football where there are several teams on the field at once. Some of the players are on all the teams, but some are playing for only one or two. Each team has goal posts in slightly different places - and each team isn't necessarily playing by the same rules. And there's no umpire.

Here's an example of how you can end up with controversy and people taking different positions even when there's a systematic review. The area of some disagreement in this subset of reviews is about psychological intervention after trauma to prevent post-traumatic stress disorder (PTSD) or other problems:

Published in 2002Published in 2005Published in 2005Published in 2010; Published in 2012Published in 2013.

The conclusions range from saying debriefing has a large benefit to saying there is no evidence of benefit and it seems to cause some PTSD. Most of the others, but not all, fall somewhere in between, leaning to "we can't really be sure". Most are based only on randomized trials, but one has none, and one has a mixture of study types.

The authors are sometimes big independent national or international agencies. A couple of others include authors of the studies they are reviewing. The definition of trauma isn't the same - they may or may not include childbirth, for example. The interventions aren't the same.

The quality of evidence is very low. And the biggest discordance - whether or not there is evidence of harm - hinges mostly on how much weight you put on one trial.

It's about debriefing. The debriefing group is much bigger than the control group because they stopped the trial early, and while it's complicated, that can be a source of bias.

The people in the debriefing group were at quite a lot higher risk of PTSD in the first place. Data for more than 20% of the people randomized is missing - and that biases the results too (it's called attrition bias). You can't be sure those people didn't return because they were depressed, for example. If so, that could change the results.

It's no wonder there's still a controversy here.


A comment with links to key papers here at PubMed Commons.


If you want to read more about debriefing, here's my post in Scientific American: Dissecting the controversy about early psychological response to disasters and trauma.


Comments

Popular posts from this blog

Austerity-A Fancy Word for Destitute.

The reason for this post is not for the folks who have been caught in the first wave of personal economic hard reality, but the next wave. Regardless of the optimism espoused by grinning leaders and sycophant press, we are entering the final stage of global economic collapse. It began in 2008 and was forestalled for five years with fudge putty, but the weight of global indebtedness cannot be propped any longer and the final crunch is imminent. Austerity measures herald the final throes.  Indications of coming austerity.   Austerity measures are the final last ditch effort, futile or not! Back in the day many of us old-timers went through periods of "hard-times". In retrospect I realize there is no comparison to yesteryear hard times and today's version. Back then, expectations were never very high for the working class, there were no sophisticated systems or conveniences anyway. In fact the difference between being "set" or not was about having treats or not. Si...

Terrifying Arctic methane levels

A peak methane level of 3026 ppb was recorded by the MetOp-B satellite at 469 mb on December 11, 2021 am. This follows a peak methane level of  3644 ppb  recorded by the MetOp-B satellite at 367 mb on November 21, 2021, pm. A peak methane level of 2716 ppb was recorded by the MetOp-B satellite at 586 mb on December 11, 2021, pm, as above image shows. This image is possibly even more terrifying than the image at the top, as above image shows that at 586 mb, i.e. much closer to sea level, almost all methane shows up over sea, rather than over land, supporting the possibility of large methane eruptions from the seafloor, especially in the Arctic.  Also, the image was recorded later than the image at the top with the 3026 ppb peak, indicating that even more methane may be on the way. This appears to be confirmed by the Copernicus forecast for December 12, 2021, 03 UTC, as illustrated by the image below, which shows methane at 500 hPa (equivalent to 500 mb). Furthermore, ...

Women and children overboard

It's the  Catch-22  of clinical trials: to protect pregnant women and children from the risks of untested drugs....we don't test drugs adequately for them. In the last few decades , we've been more concerned about the harms of research than of inadequately tested treatments for everyone, in fact. But for "vulnerable populations,"  like pregnant women and children, the default was to exclude them. And just in case any women might be, or might become, pregnant, it was often easier just to exclude us all from trials. It got so bad, that by the late 1990s, the FDA realized regulations and more for pregnant women - and women generally - had to change. The NIH (National Institutes of Health) took action too. And so few drugs had enough safety and efficacy information for children that, even in official circles, children were being called "therapeutic orphans."  Action began on that, too. There is still a long way to go. But this month there was a sign that ...